NRx Pharmaceuticals begins commercial sales of preservative‑free ketamine injection

NRx Pharmaceuticals has started selling its FDA‑approved preservative‑free ketamine injection in the United States. The company activated a 17‑person national sales force that already has relationships covering roughly 80% of the current U.S. ketamine market. Shipments are slated for January 2027 and the firm expects gross and net margins to be above 50% thanks to its blow‑fill‑seal manufacturing process.

The launch gives investors a near‑term revenue source with a high‑margin profile, as the company claims cost of goods sold are under 20% of the sales price. The commercial rollout also tests the market acceptance of a preservative‑free formulation that could address the ongoing ketamine shortage.

  • 1NRx deployed a 17‑person national sales team to market the new product.
  • 2The sales team’s relationships cover about 80% of U.S. ketamine sales.
  • 3Shipments of the preservative‑free ketamine are scheduled to start in January 2027.
  • 4NRx expects gross and net sales margins to exceed 50%.
  • 5The product uses blow‑fill‑seal technology that reduces cost of goods sold to less than 20% of the sales price.
  • 6The FDA approved the preservative‑free ketamine formulation on October 30, 2026.

Sources